Biohaven Therapeutics Ltd.
Clinical trials sponsored by Biohaven Therapeutics Ltd., explained in plain language.
A biopharmaceutical company focused on neuroscience and immunology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New obesity drug taldefgrobep alfa enters Mid-Stage trial Results expected Sep 2026 (estimated) May already have reported ↗
- New pill aims to tame seizures in Drug-Resistant epilepsy Results expected Oct 2026 (estimated) May already have reported ↗
- New hope for rare burning pain: drug trial targets genetic cause Results expected Nov 2026 (estimated) May already have reported ↗
- New epilepsy drug shows promise in reducing seizures Results expected Dec 2026 (estimated) May already have reported ↗
- New epilepsy drug safety check: 660 patients monitored long-term Results expected Dec 2026 (estimated) May already have reported ↗
-
Epilepsy drug study halted early: BHV-7000 shows limited promise
Disease control Stopped earlyThis study tested whether BHV-7000, taken alongside other medications, could reduce generalized tonic-clonic seizures in people with idiopathic generalized epilepsy. The trial was terminated early and enrolled only 27 adults aged 18-75. The main goal was to see how long it took f…
Phase 2/3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Bipolar drug study halted early – what we know
Disease control Stopped earlyThis study looked at the long-term safety of a daily drug called BHV-7000 in people with bipolar I disorder. It involved 94 participants who had completed an earlier study. The trial was terminated early, so the full safety picture is not available.
Phase 2 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC